Trinity St. James's Cancer Institute
Welcome,         Profile    Billing    Logout  
 4 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reynolds, John V
BOSTON-2, NCT03656926 / 2018-003205-25: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, Standard of Care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
03/24
03/24
BOSTON-1, NCT03657342 / 2018-003204-39: Efficacy + Safety of Liposome Cyclosporine a to Treat Bronchiolitis Obliterans Post Single Lung Transplant

Completed
3
220
Europe, US, RoW
Liposomal Cyclosporine A, L-CsA, standard of care, SoC
Zambon SpA, BREATH Therapeutics Inc.
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
04/24
04/24
NCT04460352 / 2020-000149-15: Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer

Recruiting
3
1020
Europe, Canada
Neoadjuvant radiotherapy (arm A), Carboplatin, paclitaxel, Neoadjuvant chemotherapy, Esophagectomy, Neoadjuvant radiotherapy (arm B), Neoadjuvant Platin-Taxane Regimen (alternative 1), Cisplatin, paclitaxel, Platinum-Fluoropyrimidine Regimens (alternative 2a), Oxaliplatin, calcium folinate, 5-fluorouracil, Platinum-Fluoropyrimidine Regimens (alternative 2b)
Karolinska University Hospital, University of Leipzig, The Swedish Research Council
Esophageal Squamous Cell Carcinoma
09/26
12/31
SARONG-II, NCT06115629: Surveillance After Resection of Oesophageal aNd Gastric Cancer () Trial

Not yet recruiting
3
952
Europe
Surveillance protocol
University of Dublin, Trinity College, Trinity St. James's Cancer Institute, University of Oxford, Karolinska Institutet
Esophageal Cancer, Gastric Cancer
11/26
11/29
Voxelotor, NCT05289570: for Improving Oxygen Saturation in Adults

Terminated
2
3
US
Voxelotor, Oxbryta®
Duke University
Acute Lung Injury, End Stage Lung Disease
06/23
07/23
HERA, NCT06550063: HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes

Recruiting
N/A
2188
Europe
St. James's Hospital, Ireland
Esophagus Cancer, Gastric Cancer, HER2-positive Cancer, HER2-low Cancer
05/25
08/25
METABREC, NCT04654975: Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer

Recruiting
N/A
10000
Europe, US
Esophagectomy for esophageal cancer
Universitaire Ziekenhuizen KU Leuven
Esophageal Neoplasms, Esophagectomy, Brain Metastases
03/25
03/25
Lugowska, Iwona
C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed
1/2
29
Europe, US
MEN1611, Cetuximab
Menarini Group, Menarini Ricerche S.p.A.
Metastatic Colorectal Cancer
01/24
02/24
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
NCT03906331: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Approved for marketing
N/A
Europe, Japan, US, RoW
Selpercatinib, LOXO-292, LY3527723
Eli Lilly and Company, Eli Lilly and Company
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
 
 
NCT05947903: Validation of the European Oncology Quality of Life Toolkit

Not yet recruiting
N/A
4000
Europe, RoW
Administration of the EUonQoL-Kit - Active Treatment questionnaire, Administration of the EUonQoL-Kit - Survivors questionnaire, Administration of the EUonQoL-Kit - Palliative Care questionnaire
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Gustave Roussy, Cancer Campus, Grand Paris, DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG (German Cancer Research Center), Oslo universitetssykehus HF, The Netherlands Cancer Institute, Hospital del Mar Research Institute, Istituto Europeo di Oncologia, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, EAPC, Institut Curie, EUROPEAN CANCER ORGANISATION, DIGICORE/IFO, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Alleanza Contro il Cancro, Istituti Fisioterapici Ospitalieri, STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG, University of Milan, SporeData OÜ, ORGANISATION OF EUROPEAN CANCER INSTITUTES, FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA, Medical University Innsbruck, SDRUZHENIE ASOTSIATSIA NA PATSIENTITE SONKOLOGICHNI ZABOLYAVANIA I PRIYATELI, FEDERATIA ASOCIATIILOR BOLNAVILOR DE CANCER, University of Leeds, The Leeds Teaching Hospitals NHS Trust, Region Hovedstaden (Bispebjerg Hospital & Rigshospitalet)
Cancer, Survivorship, Palliative Care
10/24
10/24
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
Donohoe, Claire
SARONG-II, NCT06115629: Surveillance After Resection of Oesophageal aNd Gastric Cancer () Trial

Not yet recruiting
3
952
Europe
Surveillance protocol
University of Dublin, Trinity College, Trinity St. James's Cancer Institute, University of Oxford, Karolinska Institutet
Esophageal Cancer, Gastric Cancer
11/26
11/29
PROPEL-2, NCT05977816: Prophylactic Negative Pressure Wound Therapy in Laparotomy Wounds

Recruiting
N/A
2000
Europe
Negative Pressure Wound Therapy, Standard wound dressing
Royal College of Surgeons, Ireland
Wound Surgical, Wound Infection, Cosmesis
01/26
07/26
Elliott, Jessie A
SARONG-II, NCT06115629: Surveillance After Resection of Oesophageal aNd Gastric Cancer () Trial

Not yet recruiting
3
952
Europe
Surveillance protocol
University of Dublin, Trinity College, Trinity St. James's Cancer Institute, University of Oxford, Karolinska Institutet
Esophageal Cancer, Gastric Cancer
11/26
11/29

Download Options